Active immunization with pneumolysin versus 23-valent polysaccharide vaccine for Streptococcus pneumoniae keratitis

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 12, 2011, Pages 9232-9243

  Norcross, Erin W ^a   Sanders, Melissa E ^a   Moore III, Quincy C ^a   Taylor, Sidney D ^a   Tullos, Nathan A ^a   Caston, Rhonda R ^a   Dixon, Sherrina N ^a   Nahm, Moon H ^b   Burton, Robert L ^b   Thompson, Hilary ^c   McDaniel, Larry S ^a   Marquart, Mary E ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYELOPEROXIDASE; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; 23 VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; OPSONIN; PLY PROTEIN, STREPTOCOCCUS PNEUMONIAE; STREPTOLYSIN;

ACTIVE IMMUNIZATION; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL KERATITIS; BACTERIAL LOAD; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED STUDY; CORNEA EPITHELIUM; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE INFLAMMATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; NONHUMAN; PASSIVE IMMUNIZATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RABBIT; SERODIAGNOSIS; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; WESTERN BLOTTING; ANIMAL; BACTERIAL COUNT; BACTERIAL EYE INFECTION; BLOOD; COMPARATIVE STUDY; CORNEA ULCER; IMMUNOLOGY; MICROBIOLOGY; PHYSIOLOGY; PNEUMOCOCCAL INFECTION; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; COLONY COUNT, MICROBIAL; CORNEAL ULCER; EYE INFECTIONS, BACTERIAL; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OPSONIN PROTEINS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RABBITS; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS; VACCINATION;

EID: 84856241048     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6968     Document Type: Article

References (89)

1. Lynch JP III, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med. 2010;16:217-225.
2. Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 1996;122:1-17.
3. Miller JJ, Scott IU, Flynn HW Jr, Smiddy WE, Corey RP, Miller D. Endophthalmitis caused by Streptococcus pneumoniae. Am J Ophthalmol. 2004;138:231-236.
4. Nouri M, Terada H, Alfonso EC, Foster CS, Durand ML, Dohlman CH. Endophthalmitis after keratoprosthesis: incidence, bacterial causes, and risk factors. Arch Ophthalmol. 2001;119:484-489.
5. Hagan M, Wright E, Newman M, Dolin P, Johnson G. Causes of suppurative keratitis in Ghana. Br J Ophthalmol. 1995;79:1024-1028.
6. Kunimoto DY, Sharma S, Reddy MK, et al. Microbial keratitis in children. Ophthalmology. 1998;105:252-257.
7. Ormerod LD, Hertzmark E, Gomez DS, Stabiner RG, Schanzlin DJ, Smith RE. Epidemiology of microbial keratitis in southern California: a multivariate analysis. Ophthalmology. 1987;94:1322-1333.
8. Martin M, Turco JH, Zegans ME, et al. An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. N Engl J Med. 2003; 348:1112-1121.
9. Crum NF, Barrozo CP, Chapman FA, Ryan MA, Russell KL. An outbreak of conjunctivitis due to a novel unencapsulated Streptococcus pneumoniae among military trainees. Clin Infect Dis. 2004; 39:1148-1154.
10. Pepose JS, Wilhelmus KR. Divergent approaches to the management of corneal ulcers. Am J Ophthalmol. 1992;114:630-632.
11. Parmar P, Salman A, Kalavathy CM, Jesudasan CA, Thomas PA. Pneumococcal keratitis: a clinical profile. Clin Exp Ophthalmol. 2003;31:44-47.
12. Bhave P, Chamie G. Streptococcus pneumoniae keratitis. J Hosp Med. 2008;3:353.
13. Bharathi MJ, Ramakrishnan R, Vasu S, Palaniappan R. Aetiological diagnosis of microbial keratitis in South India: a study of 1618 cases. Indian J Med Microbiol. 2002;20:19-24.
14. Norina TJ, Raihan S, Bakiah S, Ezanee M, Liza-Sharmini AT, Wan Hazzabah WH. Microbial keratitis: aetiological diagnosis and clinical features in patients admitted to Hospital Universiti Sains Malaysia. Singapore Med J. 2008;49:67-71.
15. Jhanji V, Moorthy S, Vajpayee RB. Microbial keratitis in patients with down syndrome: a retrospective study. Cornea. 2009;28: 163-165.
16. Dada T, Sharma N, Dada VK, Vajpayee RB. Pneumococcal keratitis after laser in situ keratomileusis. J Cataract Refract Surg. 2000; 26:460-461.
17. Keay L, Edwards K, Naduvilath T, Forde K, Stapleton F. Factors affecting the morbidity of contact lens-related microbial keratitis: a population study. Invest Ophthalmol Vis Sci. 2006;47:4302-4308.
18. Holden BA, Sweeney DF, Sankaridurg PR, et al. Microbial keratitis and vision loss with contact lenses. Eye Contact Lens. 2003;29: S131-S134.
19. Saeed A, D'Arcy F, Stack J, Collum LM, Power W, Beatty S. Risk factors, microbiological findings, and clinical outcomes in cases of microbial keratitis admitted to a tertiary referral center in Ireland. Cornea. 2009;28:285-292.
20. Wagoner MD, Al-Ghamdi AH, Al-Rajhi AA. Bacterial keratitis after primary pediatric penetrating keratoplasty. Am J Ophthalmol. 2007;143:1045-1047.
21. Zaidi TS, Priebe GP, Pier GB. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Infect Immun. 2006;74:975-983.
22. Kreger AS, Lyerly DM, Hazlett LD, Berk RS. Immunization against experimental Pseudomonas aeruginosa and Serratia marcescens keratitis: vaccination with lipopolysaccharide endotoxins and proteases. Invest Ophthalmol Vis Sci. 1986;27:932-939.
23. Georgakopoulos CD, Exarchou AM, Gartaganis SP, et al. Immunization with specific polysaccharide antigen reduces alterations in corneal proteoglycans during experimental slime-producing Staphylococcus epidermidis keratitis. Curr Eye Res. 2006;31:137-146.
24. Hume EB, Dajcs JJ, Moreau JM, O'Callaghan RJ. Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis. Infect Immun. 2000;68:6052-6055.
25. Jedrzejas MJ. Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev. 2001;65:187-207.
26. Ogunniyi AD, Grabowicz M, Briles DE, Cook J, Paton JC. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun. 2007;75:350-357.
27. Bogaert D, Hermans PW, Adrian PV, Rumke HC, de GR. Pneumococcal vaccines: an update on current strategies. Vaccine. 2004; 22:2209-2220.
28. Shah P, Swiatlo E. Immunization with polyamine transport protein PotD protects mice against systemic infection with Streptococcus pneumoniae. Infect Immun. 2006;74:5888-5892.
29. Moore QC, Bosarge JR, Quin LR, McDaniel LS. Enhanced protective immunity against pneumococcal infection with PspA DNA and protein. Vaccine. 2006;24:5755-5761.
30. Green SN, Sanders M, Moore QC, et al. Protection from Streptococcus pneumoniae keratitis by passive immunization with pneumolysin antiserum. Invest Ophthalmol Vis Sci. 2008;49:290-294.
31. Reed JM, O'Callaghan RJ, Girgis DO, McCormick CC, Caballero AR, Marquart ME. Ocular virulence of capsule-deficient Streptococcus pneumoniae in a rabbit keratitis model. Invest Ophthalmol Vis Sci. 2005;46:604-608.
32. Johnson MK, Hobden JA, Hagenah M, O'Callaghan RJ, Hill JM, Chen S. The role of pneumolysin in ocular infections with Streptococcus pneumoniae. Curr Eye Res. 1990;9:1107-1114.
33. Preventing pneumococcal disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49:1-35.
34. Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose. MMWR Morb Mortal Wkly Rep. 2004;53:177-178.
35. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics. 2010;126:186-190.
36. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46:1-24.
37. Norcross EW, Tullos NA, Taylor SD, Sanders ME, Marquart ME. Assessment of Streptococcus pneumoniae capsule in conjunctivitis and keratitis in vivo neuraminidase activity increases in nonencapsulated pneumococci following conjunctival infection. Curr Eye Res. 2010;35:787-798.
38. Tweten RK. Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect Immun. 2005;73:6199-6209.
39. Palmer M. The family of thiol-activated, cholesterol-binding cytolysins. Toxicon. 2001;39:1681-1689.
40. Paton JC, Rowan-Kelly B, Ferrante A. Activation of human complement by the pneumococcal toxin pneumolysin. Infect Immun. 1984;43:1085-1087.
41. Johnson MK, Hobden JA, O'Callaghan RJ, Hill JM. Confirmation of the role of pneumolysin in ocular infections with Streptococcus pneumoniae. Curr Eye Res. 1992;11:1221-1225.
42. Briles DE, Nahm M, Schroer K, et al. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 Streptococcus pneumoniae. J Exp Med. 1981;153:694-705.
43. Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol. 2006;44:124-131.
44. Thornton J, McDaniel LS. THP-1 monocytes up-regulate intercellular adhesion molecule 1 in response to pneumolysin from Streptococcus pneumoniae. Infect Immun. 2005;73:6493-6498.
45. Zhang Q, Choo S, Finn A. Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children. Infect Immun. 2002;70:5363-5369.
46. Skovsted IC, Kerrn MB, Sonne-Hansen J, et al. Purification and structure characterization of the active component in the pneumococcal 22F polysaccharide capsule used for adsorption in pneumococcal enzyme-linked immunosorbent assays. Vaccine. 2007; 25:6490-6500.
47. Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol. 2006;13:1004-1009.
48. Kakazu A, Sharma G, Bazan HE. Association of protein tyrosine phosphatases (PTPs)-1B with c-Met receptor and modulation of corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 2008;49:2927-2935.
49. Sharma GD, He J, Bazan HE. p38 and ERK1/2 coordinate cellular migration and proliferation in epithelial wound healing: evidence of cross-talk activation between MAP kinase cascades. J Biol Chem. 2003;278:21989-21997.
50. Harlow E, Lane D. Using Antibodies: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1999: 74-76.
51. Crowder M, Hand D. Analysis of repeated measures. In: Monographs on Statistics and Applied Probability. Boca Raton, FL: Chapman & Hall/CRC; 1990:268.
52. Edwards D, Berry JJ. The efficiency of simulation-based multiple comparisons. Biometrics. 1987;43:913-928.
53. Johnson MK, Allen JH. The role of cytolysin in pneumococcal ocular infection. Am J Ophthalmol. 1975;80:518-521.
54. Marquart ME, Monds KS, McCormick CC, et al. Cholesterol as treatment for pneumococcal keratitis: cholesterol-specific inhibition of pneumolysin in the cornea. Invest Ophthalmol Vis Sci. 2007;48:2661-2666.
55. Ogunniyi AD, Woodrow MC, Poolman JT, Paton JC. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun. 2001;69:5997-6003.
56. Alexander JE, Lock RA, Peeters CC, et al. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun. 1994;62:5683-5688.
57. Balmer P, North J, Baxter D, et al. Measurement and interpretation of pneumococcal IgG levels for clinical management. Clin Exp Immunol. 2003;133:364-369.
58. Huo ZM, Miles J, Riches PG, Harris T. Limitations of Pneumovax as a detection antigen in the measurement of serotype-specific antibodies by enzyme-linked immunosorbent assay. Ann Clin Biochem. 2002;39:398-403.
59. Huo Z, Miles J, Harris T, Riches P. Effect of Pneumovax II vaccination in high-risk individuals on specific antibody and opsonic capacity against specific and non-specific antigen. Vaccine. 2002; 20:3532-3534.
60. Targonski PV, Poland GA. Pneumococcal vaccination in adults: recommendations, trends, and prospects. Cleve Clin J Med. 2007; 74:401-410,413.
61. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective?-meta-analysis of the prospective trials. BMC Fam Pract. 2000;1:1.
62. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180: 48-58.
63. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med. 1994;154:2666-2677.
64. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine. 2001; 19:4780-4790.
65. Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis. 2003;3:71-78.
66. Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine. 2009;27:1504-1510.
67. Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother. 2006;58:117-124.
68. Burns T, Abadi M, Pirofski LA. Modulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin m monoclonal antibody to serotype 8 capsular polysaccharide. Infect Immun. 2005;73:4530-4538.
69. Tian H, Weber S, Thorkildson P, Kozel TR, Pirofski LA. Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice. Infect Immun. 2009;77:1502-1513.
70. Preston MJ, Kernacki KA, Berk JM, Hazlett LD, Berk RS. Kinetics of serum, tear, and corneal antibody responses in resistant and susceptible mice intracorneally infected with Pseudomonas aeruginosa. Infect Immun. 1992;60:885-891.
71. Mondino BJ, Brawman-Mintzer O, Adamu SA. Corneal antibody levels to ribitol teichoic acid in rabbits immunized with staphylococcal antigens using various routes. Invest Ophthalmol Vis Sci. 1987;28:1553-1558.
72. Berk RS, Montgomery IN, Hazlett LD. Serum antibody and ocular responses to murine corneal infection caused by Pseudomonas aeruginosa. Infect Immun. 1988;56:3076-3080.
73. Price KE, Camilli A. Pneumolysin localizes to the cell wall of Streptococcus pneumoniae. J Bacteriol. 2009;191:2163-2168.
74. Melin M, Jarva H, Siira L, Meri S, Kayhty H, Vakevainen M. Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun. 2009;77:676-684.
75. Wu K, Zhang X, Shi J, et al. Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae Infections in Mice. Infect Immun. 2010;78:1276-1283.
76. Ferreira DM, Areas AP, Darrieux M, Leite LC, Miyaji EN. DNA vaccines based on genetically detoxified derivatives of pneumolysin fail to protect mice against challenge with Streptococcus pneumoniae. FEMS Immunol Med Microbiol. 2006;46:291-297.
77. Zhang Q, Bernatoniene J, Bagrade L, et al. Serum and mucosal antibody responses to pneumococcal protein antigens in children: relationships with carriage status. Eur J Immunol. 2006;36:46-57.
78. Holmlund E, Quiambao B, Ollgren J, Nohynek H, Kayhty H. Development of natural antibodies to pneumococcal surface protein A, pneumococcal surface adhesin A and pneumolysin in Filipino pregnant women and their infants in relation to pneumococcal carriage. Vaccine. 2006;24:57-65.
79. Garcia-Suarez MM, Cima-Cabal MD, Florez N, et al. Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin. Infect Immun. 2004;72:4534-4540.
80. Huo Z, Spencer O, Miles J, et al. Antibody response to pneumolysin and to pneumococcal capsular polysaccharide in healthy individuals and Streptococcus pneumoniae infected patients. Vaccine. 2004;22:1157-1161.
81. Musher DM, Phan HM, Baughn RE. Protection against bacteremic pneumococcal infection by antibody to pneumolysin. J Infect Dis. 2001;183:827-830.
82. Francis JP, Richmond PC, Pomat WS, et al. Maternal antibodies to pneumolysin but not to pneumococcal surface protein A delay early pneumococcal carriage in high-risk Papua New Guinean infants. Clin Vaccine Immunol. 2009;16:1633-1638.
83. Zaidi TS, Zaidi T, Pier GB. Role of neutrophils, MyD88-mediated neutrophil recruitment, and complement in antibody-mediated defense against Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci. 2010;51:2085-2093.
84. Zaidi TS, Lyczak J, Preston M, Pier GB. Cystic fibrosis transmembrane conductance regulator-mediated corneal epithelial cell ingestion of Pseudomonas aeruginosa is a key component in the pathogenesis of experimental murine keratitis. Infect Immun. 1999;67:1481-1492.
85. Billiau A, Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol. 2001;70:849-860.
86. Pletz MW, Maus U, Hohlfeld JM, Lode H, Welte T. Pneumococcal vaccination: conjugated vaccine induces herd immunity and reduces antibiotic resistance (in German). Dtsch Med Wochenschr. 2008;133:358-362.
87. Feldman C, Mitchell TJ, Andrew PW, et al. The effect of Streptococcus pneumoniae pneumolysin on human respiratory epithelium in vitro. Microb Pathog. 1990;9:275-284.
88. Briles DE, Hollingshead S, Brooks-Walter A, et al. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine. 2000;18:1707-1711.
89. Roche H, Ren B, McDaniel LS, Hakansson A, Briles DE. Relative roles of genetic background and variation in PspA in the ability of antibodies to PspA to protect against capsular type 3 and 4 strains of Streptococcus pneumoniae. Infect Immun. 2003;71:4498-4505.